A Wall Street analyst has provided a review for the Healthcare company yesterday, but retained the same rating on the stock. Analyst Douglas Miehm from RBC Capital rated Oncolytics Biotech (ONC) a Buy, setting a C$10 price target.
According to TipRanks.com, Miehm is ranked #4871 out of 5231 analysts.
Read also: Tilray (TLRY) Ramping up Cannabis Supply in Canada with Acquisition of Natura Naturals Holdings
Oncolytics Biotech has an analyst consensus of Moderate Buy.
Based on Oncolytics Biotech’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of C$3.34 million. In comparison, last year the company had a GAAP net loss of C$4.75 million.
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus called REOLYSIN. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
The company’s shares closed on Monday at C$2.55, close to its 52-week low of C$2.26.
